[go: up one dir, main page]

NO20082919L - Heteroringsubstituerte 3-alkylazetidinderivater - Google Patents

Heteroringsubstituerte 3-alkylazetidinderivater

Info

Publication number
NO20082919L
NO20082919L NO20082919A NO20082919A NO20082919L NO 20082919 L NO20082919 L NO 20082919L NO 20082919 A NO20082919 A NO 20082919A NO 20082919 A NO20082919 A NO 20082919A NO 20082919 L NO20082919 L NO 20082919L
Authority
NO
Norway
Prior art keywords
disorders
treatment
useful
compounds
receptor
Prior art date
Application number
NO20082919A
Other languages
English (en)
Inventor
Robert K Baker
Shouwu Miao
Kathleen M Rupprecht
Jeffrey J Hale
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20082919L publication Critical patent/NO20082919L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nye forbindelser med strukturformel (I) er antagonister og/eller inversagonister mot reseptoren for cannabinoid-1 (CB1), og er anvendbare ved behandling, forebygging og undertrykkelse av sykdommer formidlet av CB1-reseptoren. Forbindelsene ifølge den foreliggende oppfinnelse er anvendbare som sentraltvirkende legemidler ved behandling av psykose, hukommelsessvikt, kognitive forstyrrelser, Alzheimers sykdom, migrene, nevropati, nevro-inflammatoriske forstyrrelser, inkludert multippel sklerose og GuillainBarre-syndrom, og de inflammatoriske følgesykdommer av viral encefalitt, cerebrale vaskulære forstyrrelser og hodetraume, angstforstyrrelser, stress, epilepsi, Parkinsons sykdom, bevegelsesforstyrrelser og schizofreni. Forbindelsene er også anvendbare til behandling av stoffmisbruksforstyrrelser, behandling av overvekt eller spiseforstyrrelser, samt behandling av astma, forstoppelse, kronisk intestinal pseudoobstruksjon og cirrhose i leveren.
NO20082919A 2005-11-28 2008-06-27 Heteroringsubstituerte 3-alkylazetidinderivater NO20082919L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74018305P 2005-11-28 2005-11-28
PCT/US2006/045328 WO2007062193A1 (en) 2005-11-28 2006-11-22 Heterocycle-substituted 3-alkyl azetidine derivatives

Publications (1)

Publication Number Publication Date
NO20082919L true NO20082919L (no) 2008-08-27

Family

ID=37779312

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082919A NO20082919L (no) 2005-11-28 2008-06-27 Heteroringsubstituerte 3-alkylazetidinderivater

Country Status (15)

Country Link
EP (1) EP1954692A1 (no)
KR (1) KR20080073721A (no)
AR (1) AR058199A1 (no)
BR (1) BRPI0619018A2 (no)
CR (1) CR10014A (no)
DO (1) DOP2006000261A (no)
EC (1) ECSP088477A (no)
IL (1) IL191586A0 (no)
MA (1) MA30086B1 (no)
NO (1) NO20082919L (no)
PE (1) PE20070647A1 (no)
RU (1) RU2008126248A (no)
SV (1) SV2009002917A (no)
TW (1) TW200804317A (no)
WO (1) WO2007062193A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008317482A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Synthesis and crystalline forms of CB-1 antagonist/inverse agonist
WO2012031220A2 (en) 2010-09-03 2012-03-08 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
CN1802351A (zh) * 2003-06-11 2006-07-12 麦克公司 被取代的3－烷基和3－链烯基氮杂环丁烷衍生物
WO2006119260A2 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity

Also Published As

Publication number Publication date
EP1954692A1 (en) 2008-08-13
DOP2006000261A (es) 2007-07-15
TW200804317A (en) 2008-01-16
PE20070647A1 (es) 2007-08-11
RU2008126248A (ru) 2010-01-10
BRPI0619018A2 (pt) 2016-11-29
SV2009002917A (es) 2009-02-19
ECSP088477A (es) 2008-06-30
MA30086B1 (fr) 2008-12-01
WO2007062193A1 (en) 2007-05-31
IL191586A0 (en) 2008-12-29
KR20080073721A (ko) 2008-08-11
AR058199A1 (es) 2008-01-23
CR10014A (es) 2008-07-29

Similar Documents

Publication Publication Date Title
NO20082919L (no) Heteroringsubstituerte 3-alkylazetidinderivater
DE60316829D1 (de) Substituierte furoä2,3-büpyridin derivate
NO20060141L (no) Substituerte 3-alkyl- og 3-alkenylazetidinderivater
DE60334787D1 (de) Substituierte amide
EP1492784A4 (en) SUBSTITUTED 2,3-DIPHENYLPYRIDINES
JO2482B1 (en) Amide compounds by replacement
WO2003082190A3 (en) Spirocyclic amides as cannabinoid receptor modulators
WO2003063781A3 (en) Substituted imidazoles as cannabinoid receptor modulators
WO2004058145A3 (en) Substituted amides
WO2004029204A3 (en) Substituted pyrimidines
ATE452890T1 (de) Substituierte naphthyridinonderivate
WO2003086288A3 (en) Bicyclic amides
AU2016299485B2 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
ATE501151T1 (de) Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren
WO2005027837A3 (en) Substituted sulfonamides
WO2008024284A3 (en) Sulfonylated piperazines as cannabinoid-1 receptor modulators
NO20063381L (no) CB1 modulatorforbindelser
NO20054206L (no) Bifenylderivater
WO2007136607A3 (en) Substituted esters as cannabinoid-1 receptor modulators
WO2004069794A3 (en) New arylpiperazinyl compounds
TW200400185A (en) Derives de 1-piperazinylacylpiperidine substitues, leur preparation et leur application en therapeutique
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
WO2007064566A3 (en) Heterocycle-substituted 3-alkyl azetidine derivatives
WO2006041797A3 (en) Acyclic hydrazides as cannabinoid receptor modulators
WO2010012811A3 (en) Method for screening of 5ht7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application